Teijin Limited

Teijin Pharma Limited

Toshihiro Ishii

Gen Unoki

Takaharu Tsutsumi

Yuri Sakai

Akira Nakano

Satoshi Sugiura

Masanori Yamamoto

Yoshiyuki Matsumoto

Kenichiro Kataoka

Tomomi Kosugi

Reiko Takarada

Hiroko Ogawa

Takahiro Takeuchi

Masahiro Koga

A compound having GSK-3 inhibitory activity.  Aand Aare a single bond, an aliphatic hydrocarbon group; Aand Aare a single bond, CO, COO, CONR, O, OCO, NR, NRCO, NRCOO, etc.; Gis a single bond, an aliphatic hydrocarbon, aromatic hydrocarbon, heterocyclic; Gis H, an aliphatic hydrocarbon, an alicyclic hydrocarbon, an aromatic hydrocarbon, heterocyclic; Ais a single bond, NR; Ris H, halogen, an aliphatic hydrocarbon, alicyclic hydrocarbon, aromatic hydrocarbon, heterocyclic; Ais a single bond, NR, CO, NRCO, NRCONR, CONR, COO, O, etc.; Ris H, halogen, nitro, saturated aliphatic hydrocarbon, alicyclic hydrocarbon, aromatic hydrocarbon, heterocyclic; and Rmay be a trimethylsilyl, formyl, acyl, carboxyl, alkoxylcarbonyl, carbamoyl, alkylcarbamoyl, or cyano group when Ais CR&#x2550;CR or C&#x2261;C, wherein R is H or an lower aliphatic hydrocarbon group.

Substituted pyrrolo[3,2-d]pyrimidine derivatives

The invention provides pyrrolo[3,2-d]pyrimidine derivatives represented by formula (I), and their medically acceptable salts. The compounds of the invention exhibit GSK-3 inhibiting activity and are therefore expected to be useful as therapeutic or prophylactic agents for conditions in which GSK-3 is implicated, such as diabetes, diabetes complications, Alzheimer's disease, neurodegenerative diseases, manic depression, traumatic encephalopathy, alopecia, inflammatory diseases, cancer and immune deficiency. 

Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors

Growing community of inventors

Hino, Japan

Toshihiro Ishii